Important Update for Healthcare Professionals: Opella Healthcare France
On 24 October 2025, the pharmaceutical company Opella Healthcare France S.A.S. (on behalf of the product) issued a letter to healthcare professionals notifying of a new contraindication for Phenergan oral formulations (25 mg film-coated tablets and 5 mg/5 ml oral solution). HPRA Assets What’s Changed Why This Matters The new contraindication recognises the risk of […]